LCTX vs REGN: Which Stock is Better?
Side-by-side comparison of Lineage Cell Therapeutics Inc and Regeneron Pharmaceuticals Inc in 2026
LCTX
Lineage Cell Therapeutics Inc
$1.71
REGN
Regeneron Pharmaceuticals Inc
$750.57
Key Metrics Comparison
| Metric | LCTX | REGN | Winner |
|---|---|---|---|
| Market Cap | $408.50M | $78.87B | REGN |
| P/E Ratio | N/A | 17.98 | REGN |
| EPS (TTM) | $N/A | $41.48 | REGN |
| Revenue Growth | 1.3% | 0.0% | LCTX |
| Gross Margin | -22.8% | 44.6% | REGN |
Analyze LCTX
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is LCTX or REGN a better investment?
Comparing LCTX and REGN: Lineage Cell Therapeutics Inc has a market cap of $408.50M while Regeneron Pharmaceuticals Inc has $78.87B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between LCTX and REGN?
LCTX (Lineage Cell Therapeutics Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: LCTX or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: LCTX or REGN?
LCTX has higher revenue growth at 1.3% vs 0.0% for REGN.
Which company is more profitable: LCTX or REGN?
Regeneron Pharmaceuticals Inc (REGN) has higher gross margins at 44.6% compared to -22.8% for LCTX.
Which is the larger company: LCTX or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $78.87B compared to $408.50M for LCTX.
Should I buy LCTX or REGN in 2026?
Both LCTX and REGN have investment merit. LCTX trades at $1.71 while REGN trades at $750.57. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between LCTX and REGN stock?
Key differences: Market Cap ($408.50M vs $78.87B), P/E Ratio (N/A vs 18.0x), Revenue Growth (1.3% vs 0.0%), Gross Margin (-22.8% vs 44.6%).